NUVL Stock Analysis: Buy, Sell, or Hold?
NUVL - Nuvalent, Inc. Class A Common Stock
$102.89
0.46 (0.45%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 26, 2026
25d
Get Alerted When NUVL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NUVL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NUVL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NUVL is currently trading at $102.89, which is considered fair relative to its 30-day fair value range of $100.29 to $107.22.
Technical Outlook: Technically, NUVL is in a strong uptrend. The price is currently testing key support at $100.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NUVL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $141.71 (+38.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NUVL is in a strong uptrend. The price is currently testing key support at $100.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NUVL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $141.71 (+38.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$100.29 -
$107.22
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.3% below Wall St target ($141.71)
Fair Price Analysis
30-Day Fair Range
$100.29 -
$107.22
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$5.95
(5.8%)
Support & Resistance Levels
Support Level
$100.19
Resistance Level
$113.02
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-18.28
Wall Street Target
$141.71
(+38.3%)
Last updated: January 31, 2026 1:08 PM ET
Data refreshes hourly during market hours. Next update: 2:08 PM
Data refreshes hourly during market hours. Next update: 2:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUVL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Deborah Ann Miller
SELL
5000 shares
2025-10-20
Deborah Ann Miller
SELL
12376 shares
2025-10-16
James Richard Porter
SELL
27000 shares
2025-10-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced NUVL Option Strategies
Professional options setups generated by AI based on today's NUVL price and gamma walls.
